ADMA is the ticker symbol for ADMA BIOLOGICS, INC., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks ADMA with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is ADMA a good stock to buy?

13F Pro's AI ranking engine scores ADMA at 69.7/100, ranked #248 of 2,960 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for ADMA is available at https://13fpro.ai/company/ADMA. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source ADMA data?

All ADMA BIOLOGICS, INC. fundamentals and ownership data come directly from SEC EDGAR. ADMA BIOLOGICS, INC. files with the SEC under CIK 1368514. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

ADMA BIOLOGICS, INC.(ADMA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

ADMA BIOLOGICS, INC. (ADMA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADMA at 69.7/100 on a 32-signal composite quality model, placing it at rank #248 of 2,960 stocks — the top 10% of the AI-ranked universe. ADMA scores in the top quartile across balance sheet strength (98.0), profitability (86.8), revenue growth (86.0). Areas of concern include institutional flow (12.8) and revenue scale (37.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ADMA BIOLOGICS, INC. reports quarterly revenue of $124.4M, net income of $37.8M, an operating margin of 42.2%. Top institutional holders of ADMA by reported 13-F value include BlackRock, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ADMA trades on the Nasdaq exchange and files with the SEC under CIK 1368514. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADMA BIOLOGICS, INC. directly from SEC EDGAR.

AI Quality Score

69.7/100

AI Rank

#248

Revenue

$124.4M

Net Income

$37.8M

Free Cash Flow

$27.3M

Operating Margin

42.2%

ADMA key financials by period

ADMA BIOLOGICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K	$510.2M	$146.9M	37.5%
FY 2024	10-K	$426.5M	$197.7M	32.6%
FY 2023	10-K	$258.2M	$-28.2M	8.4%
FY 2022	10-K	$154.1M	$-65.9M	-25.6%
FY 2021	10-K	$80.9M	$-71.6M	-72.1%
FY 2020	10-K	$42.2M	$-75.7M	-153.8%

Institutions holding ADMA

Institutional investors reporting a position in ADMA BIOLOGICS, INC. on SEC Form 13F.
Institution	Shares	Value	Reported
BlackRock	38,355,684	$321.0M	2026-06-30
STATE STREET	17,116,022	$143.3M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	10,103,809	$84.6M	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT	10,088,490	$84.4M	2026-06-30
Rubric Capital Management	9,339,414	$78.2M	2026-06-30
Capital Research Global Investors	8,756,374	$73.3M	2026-06-30
FIRST ADVISORS	7,798,351	$65.3M	2026-06-30
GEODE CAPITAL MANAGEMENT	6,059,984	$50.7M	2026-06-30
Caligan Partners	5,725,007	$47.9M	2026-06-30
D. E. Shaw	5,274,597	$44.1M	2026-06-30

SEC EDGAR: CIK 1368514 →

ADMA BIOLOGICS, INC.

ADMA

NasdaqMid CapHealthcare

13F Pro Quality Score

69.7/100

Rank #248 of 2,960 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

86.0/100

Profitability

86.8/100

Balance Sheet

98.0/100

Earnings Quality

59.3/100

Free Cash Flow

76.3/100

Institutional Flow

12.8/100

Revenue Scale

37.8/100

Dilution Risk

28.0/100

Price Chart

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

What's Driving ADMA's Business? Latest 10-Q Breakdown

AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

ADMA's Q2 revenue grew just 2.0% to $124.4M as 23.5% ASCENIV growth was nearly offset by a 48.5% BIVIGAM decline from competitive IVIG pricing pressure, while gross margin expanded sharply to 69.4% from 55.1%.

Biggest Revenue Drivers

ADMA BioManufacturing$123.6M+1.4% YoY

Plasma Collection Centers$0.7M+100.0% YoY

Biggest Revenue Drivers

Total revenue: $124.4M+2.0% YoY

ADMA BioManufacturing$123.6M+1.4% YoY

Within ADMA BioManufacturing

ASCENIV$102.9M+23.5% YoY

Reflects continued growth in market acceptance of the product

BIVIGAM$19.4M-48.5% YoY

Reflects continued competitive pressures in the standard immune globulin market

Plasma Collection Centers$0.7M+100.0% YoY

Largest Expense Items

Selling, general and administrative$26.7M+20.4% YoY

Higher employee-related costs, increased software maintenance costs, and higher professional and legal fees tied to ongoing litigation and strategic initiatives

Research and development$6.0M+383% YoY

Ramp-up of clinical development and trial activities related to the SG-001 development project

Plasma center operating expenses$1.0M-10.9% YoY

Decrease primarily due to the sale of three plasma centers in the first quarter of 2026

Margins: Gross margin rose to 69.4% from 55.1% a year ago, driven by favorable product mix (higher ASCENIV, lower BIVIGAM) and margin benefits from the FDA-approved yield enhancement manufacturing process.

Watch Items from the Filing

Three customers represented approximately 76% of Q2 2026 consolidated revenues; two customers (BioCare and CuraScript) represented approximately 81% of accounts receivable at quarter-end.
On July 10, 2026 a putative securities class action (Mazzarino v. ADMA) was filed against the company and certain officers alleging Exchange Act violations; damages unspecified and no accrual recorded.
New FDA-approved IVIG products entering the market with aggressive pricing tactics (extended payment terms, rebates, discounts) drove the 48.5% BIVIGAM revenue decline and elevated industry-wide inventory.
Company borrowed $125.0M under its JPM Revolving Facility to fund an accelerated share repurchase, leaving $198.1M in variable-rate debt outstanding as of June 30, 2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →